Medical/Pharmaceuticals

Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers

Clinical Decisions product suite from EBSCO earns recognition for modern evidence-based resources that support clinical decision-making, enhance patient satisfaction, and improve outcomes SAN ANTONIO, June 7, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical decision support syst...

2022-06-07 21:00 2246

Nature Scientific Reports to publish novel decentralized federated AI learning algorithm that connects globally distributed data silos containing private and poor-quality data

SAN FRANCISCO, June 7, 2022 /PRNewswire/ -- Nature Scientific Reports journal has published results of a new decentralized federated AI learning algorithm from Presagen that can train AI on data that is distributed globally, without having to move private data to a central location. The breakthro...

2022-06-07 20:38 1887

Molecular Stethoscope, Inc. announces new investment from the Alzheimer's Drug Discovery Foundation

Investment by the ADDF will accelerate the translation of Molecular Stethoscope's cf-mRNA liquid biopsy technology platform into products and services for the diagnosis and management of Alzheimer's disease SOUTH SAN FRANCISCO, Calif., June 7, 2022 /PRNewswire/ -- Molecular Stethoscope, a leadin...

2022-06-07 18:00 1479

Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting

KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...

2022-06-07 14:00 1859

SCG Cell Therapy And A*STAR's IMCB Collaborate To Accelerate Clinical Translation of Immune Cell-based Therapy

* The collaboration agreement works toward accelerating the study of SCG's immunotherapy pipeline and candidates such as CAR-T, TCR-T therapies, antibodies, and vaccines. * SCG will contribute its proprietary technologies to the therapeutic development of immune cell-based therapy candidates....

2022-06-07 12:23 2646

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathway. – This Phase I study will evaluate the safety, pharmacology and prelim...

2022-06-07 11:34 2310

Pharmactive Enters Strategic Partnership with Nutraconnect for APAC

Pharmactive targets Asia Pacific Market with new collaboration MADRID, June 7, 2022 /PRNewswire/ -- Pharmactive Biotech Products , S.L.U., announces a new strategic partnership withSingapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically ...

2022-06-07 09:00 1992

CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022

* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significant and clinically meaningful overall survival improvement in combination with chemotherapy for patients with treatment-naïve stage IV non-small cell lung cancer across both squamous and non-squamous ...

2022-06-07 08:02 2514

Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

* In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. * In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. * In 12 patients with brain metastasis and measurable...

2022-06-07 08:00 2398

Telix Showcasing Innovation in Theranostics at SNMMI

MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held inVancouver from June 11-14. Gallium-based pr...

2022-06-07 05:00 2097

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) FLORENCE, Ita...

2022-06-06 23:07 2860

Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"

LONDON and HONG KONG, June 6, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. The Company recorded strong opera...

2022-06-06 21:55 5068

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...

2022-06-06 21:00 2288

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...

2022-06-06 21:00 2361

Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel

PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement withargenx...

2022-06-06 19:00 1809

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

* SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). * NeuroAiD was safe as add-on treatment in patients with severe SCI. * One third of patients improved on AS...

2022-06-06 18:07 1578

CPHI China opens for international partnering after China rises in CPHI Index

The CPHI China Hosted Buyer Programme is empowering new partnering in China SHANGHAI, June 6, 2022 /PRNewswire/ -- CPHI & P-MEC China  opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country report stron...

2022-06-06 16:51 4337

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...

2022-06-06 13:15 2404

GILEAD SCIENCES APPOINTS DUSTIN HAINES AS NEW LEADER FOR ASIA 5 REGION

-- Mr Haines Brings a Strong Track Record of Global Commercial Successes and Corporate Leadership with a Career that Spans 20 Years in Pharmaceuticals -- -- He Joins Gilead's Asia 5 Team as the Company Celebrates 10 Years of Presence inAsia -- HONG KONG, June 6, 2022 /PRNewswire/ -- Gilead Scien...

2022-06-06 11:00 3504

Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO

SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that data from a phase II clinical study of KN026 (HER2 bispecific antibody) monotherapy in patients with previously treated, advance...

2022-06-06 10:49 2446
1 ... 142143144145146147148 ... 382